Pharmacological Study for Breast Cancer

"There are 20 ongoing clinical trials researching Pharmacological Study. 0 of these research projects have reached Phase 3 and most originate from Richmond, Virginia. However, there are a total 130 locations running studies for Pharmacological Study across the globe."

"Unfortunately, this clinical trial is not currently enrolling new patients. However, there are 2373 trials for carcinoma and 20 Pharmacological Studies that are presently searching for participants."

"Currently, there are 7 operational sites for this study with more to open in the future. The locations include Duarte, Mission Hills and Rancho Cucamonga. If you enroll in the program, you will be assigned to a location nearest you in order to reduce travel time requirements."

"The primary outcome of this study is the incidence of grade 2 or higher toxicities, which will be measured over 28 days per cycle up to 1 year. Secondary objectives include volume of distribution (estimated using population PK methods), overall response rate (measured by Response Evaluation Criteria in Solid Tumors [RECIST]), and IL-6, CRP, and D-dimer analysis. Generalized linear models and graphical methods will be used to explore factors as identified by serum biomarkers that may be predictive of toxicity dose reductions, dose holds or hospitalizations."

"Unfortunately, this study is not presently looking for new participants. The original posting date was December 2nd, 2016 and the most recent update occurred on August 31st, 2022. However, there are 20 other trials in the same field that are currently enrolling patients."

"While there is data supporting the safety of this pharmacological study, it only exists in Phase 2 trials. This means that, while promising, there is no clinical evidence yet to support its efficacy."